ORICOric Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Oric Pharmaceuticals, Inc. against Pharmaceutical Preparations — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| 기업 | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ORIC본 종목 | $1.3B#8 | — | 3.5x#6 | — | — | -1.3%#5 | — | -34.0%#9 | -40.4%#4 | — | 22.6%#10 | — |
| TYRA | $1.5B#1 | — | 4.1x#9 | — | — | -38.7%#8 | — | -33.9%#8 | — | — | 101.1%#7 | — |
| RARE | $1.4B#2 | — | — | 2.1x#2 | 20.2%#3 | -1.1%#4 | -79.5%#4 | — | — | — | -49.5%#14 | — |
| DMRA | $1.4B#3 | 3.0x#2 | 2.7x#4 | — | — | -878.8%#13 | — | -40.7%#10 | — | — | 675.3%#3 | — |
| TRAX | $1.4B#4 | — | 8.3x#12 | — | — | — | — | 0.0%#1 | — | — | — | — |
| AVBP | $1.4B#5 | — | 3.8x#7 | — | — | -106.6%#11 | — | -45.3%#11 | — | — | 62.0%#8 | — |
| LBRX | $1.4B#6 | 1.8x#1 | 4.1x#8 | — | — | 60.1%#3 | — | -7.6%#4 | — | — | 157.7%#5 | — |
| OMER | $1.3B#7 | 10.7x#3 | — | 18.1x#5 | -34.0%#5 | 97.9%#1 | -166.4%#5 | — | -151.8%#6 | — | 353.6%#4 | — |
| HROW | $1.2B#9 | — | 81.8x#13 | 4.6x#4 | 36.4%#1 | 70.6%#2 | 11.2%#1 | -33.8%#7 | 13.2%#2 | 6#1 | -23.1%#12 | — |
| AKTS | $1.2B#10 | — | 2.5x#3 | — | — | — | — | 0.0%#1 | — | — | 24872.7%#1 | — |
| ANRO | $1.2B#11 | — | 5.5x#10 | — | — | -2.9%#6 | — | -28.8%#5 | — | — | 704.3%#2 | — |
| OPK | $1.2B#12 | — | 1.0x#1 | 2.0x#1 | -14.9%#4 | -324.0%#12 | -19.3%#3 | -19058.1%#13 | -13.3%#3 | 4#2 | 16.1%#11 | — |
| SPTX | $1.2B#13 | — | 2.8x#5 | — | — | — | — | 0.0%#1 | — | — | — | — |
| MNKD | $1.2B#14 | — | — | 3.3x#3 | 22.2%#2 | -78.7%#9 | 11.1%#2 | — | 2283.8%#1 | — | -33.5%#13 | — |
| SVRA | $1.1B#15 | — | 7.7x#11 | 4329.1x#6 | — | -23.9%#7 | -48072.8%#6 | -82.7%#12 | -93.6%#5 | — | 50.8%#9 | — |
| JBIO | $1.1B#16 | — | 2.5x#2 | — | — | -83.0%#10 | — | -29.0%#6 | — | — | 144.4%#6 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Table built 2026-09-18.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice